CAR-T and engineered T cell therapies

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

83 papers

Active filtersClassification:Supporting

Showing 49-60 of total 83 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedSupporting evidence

An inducible signal 1 booster overcomes limited access to antigen for solid tumor cell therapy.

Radecki KC; Manry D; Kirsh C; Kumar N; McLeod E; Krishnagiri A; Flynn AD; Sima A; Oh J; Partin AC; DiAndreth B; Kamb A

2026PubMedDirectly related

Functional genomics-guided design of CAR-T and CAR-NK therapies in hematological malignancies: aligning cellular engineering with immune escape and microenvironmental resistance.

Cai S; Tan Y; Yang Q; Huang J

Jan 1, 2026Frontiers in genome editing

2026PubMedSupporting evidence

Antigen Spreading via Localized Administration Enhances Adoptive TCR-T Cell Therapy in Pancreatic Cancer.

Huang J; Wang Q; Yao Z; Wang Q; Ji Y; Yang M; Wang M; Shao S; Zhao X; Zhang F; Liang T; Hu Q

Jan 1, 2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)

2026PubMedSupporting evidence

CD19 CAR-T cell therapy in large B-cell lymphoma: clinical evidence, resistance, toxicity, and precision strategies.

Wang C; Zhu J; Qiao J; Wang H; Liang X

Jan 1, 2026Frontiers in immunology

2026PubMedSupporting evidence

Hattrick against Lymphoma with Trispecific CAR T Cells.

Merz M; Luttwak E

Jan 1, 2026Blood cancer discovery

2026PubMedSupporting evidence

Minor histocompatibility antigen TCR-T.

Krakow EF; Bleakley M

Jan 1, 2026Blood advances

2026PubMedSupporting evidence

Real-World Data from a Single-Center, Large Academic Centralized Manufacturing of CD19 CAR T Cells in an Industry Partnership.

Kebbel K; Schmiedeknecht G; Quaiser A; Schumann S; Poch C; Haß M; Grahnert A; Rodrigues M; Reiche K; Kreuz M; Koehl U

Jan 1, 2026Human gene therapy

2026PubMedSupporting evidence

T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia.

Noll JH; Dersh D; Li JY; Hemani H; Lavorando M; Bartoszek R; Amses KR; Jain A; Minehart J; Ho M; Ramirez-Fernandez A; Paruzzo L; Shestov MA; Camerini E; Peters FS; Huang X; Loren AW; Woyach JA; Goronzy JJ; Kater AP; Ruella M; Byrd JC; Powell DJ Jr; Gill SI; Porter DL; Schuster SJ; Bushman FD; Siegel DL; Levine BL; June CH; Frey NV; Cohen AD; Garfall AL; Long M; Maus MV; Weng NP; Diorio C; Fraietta JA

Jan 1, 2026Blood

2025CrossrefSupporting evidence10 citations

Basic rules to respond to PD-1 blockade cancer immunotherapy

Antoni Ribas

May 1, 2025Journal for ImmunoTherapy of Cancer

2025CrossrefSupporting evidence10 citations

Basic rules to respond to PD-1 blockade cancer immunotherapy

Antoni Ribas

May 1, 2025Journal for ImmunoTherapy of Cancer

2025CrossrefSupporting evidence0 citations

CAR-T manufacturing intensification: the next wave of CAR-T commercialization

Alexey Bersenev; Emilie Kleiren; John Knighton; Paul Bowles

Apr 3, 2025Cell and Gene Therapy Insights

2023OpenAlexSupporting evidence17 citations

Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy

Theo Lorenzini; Bruno L. Cadilha; Hannah Obeck; Mohamed-Reda Benmebarek; Florian Märkl; Stefanos Michaelides; Thaddäus Strzalkowski; Daria Briukhovetska; Philipp Jie Müller; Sayantan Nandi; Pia Winter; Lina Majed; Ruth Grünmeier; Matthias Seifert; Svenja Rausch; Tobias Feuchtinger; Stefan Endres; Sebastian Kobold

Jul 4, 2023British Journal of Cancer